North America Expansion Ypsomed is investing in a new 160,000 square-foot manufacturing facility in North Carolina, USA, marking its first manufacturing site in North America and signaling a strong growth stance to serve the US market and nearby regions.

Expanded US Footprint Recent plans include additional facilities in Texas and San Diego, reinforcing capacity and regional access for pharmaceutical and biotech partners seeking reliable self-injection platforms in the Americas.

Next Gen Platform With a focus on self-injection solutions for multiple indications, Ypsomed offers a comprehensive platform of pens, autoinjectors, and on-body devices ready to integrate with digital health services, presenting opportunities to embed connectivity and data analytics into partner therapies.

Manufacturing Scale Investments in tool and mold making facilities in Switzerland and Solothurn aim to double injection mold output, enabling faster time-to-market and higher-volume production for CIMs and device components tailored to partner pipelines.

Strategic Focus Following the pivot to exclusive self-injection solutions for chronic conditions, there are openings to collaborate on end-to-end therapy management, patient adherence programs, and payer-facing value propositions leveraging Ypsomed’s integrated device ecosystem.